Rapid Targeted Sequencing Using Dried Blood Spot Samples for Patients With Suspected Actionable Genetic Diseases
10.3343/alm.2023.43.3.280
- Author:
Man Jin KIM
1
;
Soo Yeon KIM
;
Jin Sook LEE
;
Sanggoo KANG
;
Lae-Jeong PARK
;
Wooyong CHOI
;
Ju Yeol JUNG
;
Taehyung KIM
;
Sung Sup PARK
;
Jung Min KO
;
Moon-Woo SEONG
;
Jong Hee CHAE
Author Information
1. Department of Genomic Medicine, Seoul National University Hospital, Seoul, Korea
- Publication Type:Original Article
- From:Annals of Laboratory Medicine
2023;43(3):280-289
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:New genome sequencing technologies with enhanced diagnostic efficiency have emerged. Rapid and timely diagnosis of treatable rare genetic diseases can alter their medical management and clinical course. However, multiple factors, including ethical issues, must be considered. We designed a targeted sequencing platform to avoid ethical issues and reduce the turnaround time.
Methods:We designed an automated sequencing platform using dried blood spot samples and a NEOseq_ACTION panel comprising 254 genes associated with Mendelian diseases having curable or manageable treatment options. Retrospective validation was performed using data from 24 genetically and biochemically confirmed patients. Prospective validation was performed using data from 111 patients with suspected actionable genetic diseases.
Results:In prospective clinical validation, 13.5% patients presented with medically actionable diseases, including short- or medium-chain acyl-CoA dehydrogenase deficiencies (N=6), hyperphenylalaninemia (N=2), mucopolysaccharidosis type IVA (N=1), alpha thalassemia (N=1), 3-methylcrotonyl-CoA carboxylase 2 deficiency (N=1), propionic acidemia (N=1), glycogen storage disease, type IX(a) (N=1), congenital myasthenic syndrome (N=1), and citrullinemia, type II (N=1). Using the automated analytic pipeline, the turnaround time from blood collection to result reporting was <4 days.
Conclusions:This pilot study evaluated the possibility of rapid and timely diagnosis of treatable rare genetic diseases using a panel designed by a multidisciplinary team. The automated analytic pipeline maximized the clinical utility of rapid targeted sequencing for medically actionable genes, providing a strategy for appropriate and timely treatment of rare genetic diseases.
